Renal denervation for uncontrolled hypertension: a systematic review and meta-analysis examining multiple subgroups.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
15 Apr 2024
15 Apr 2024
Historique:
medline:
18
4
2024
pubmed:
18
4
2024
entrez:
18
4
2024
Statut:
aheadofprint
Résumé
This systematic review and meta-analysis was conducted to assess the randomized controlled trial (RCT) evidence available for renal denervation (RDN) in uncontrolled arterial hypertension. Twenty-five RCTs met the eligibility criteria for the systematic review, and 16 RCTs were included in the meta-analysis. The results of the random effects meta-analysis estimated a mean difference of -8.5 mmHg [95% confidence interval (CI) -13.5 to -3.6] for office SBP, -3.6 mmHg (95% CI -5.2 to -2.0) for 24 h SBP and -3.9 mmHg (95% CI -5.6 to -2.2) for ambulatory daytime SBP in favour of RDN compared with control (medication and/or sham-only) at primary follow-up. Similarly favourable results were observed across a range of prespecified subgroup analyses, including treatment-resistant hypertension. This meta-analysis suggests that the use of RDN in uncontrolled hypertension leads to consistent reductions in blood pressure. Reductions appear to be statistically consistent in the presence or absence of medications and in populations resistant to the use of three medications.
Identifiants
pubmed: 38634457
doi: 10.1097/HJH.0000000000003727
pii: 00004872-990000000-00452
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
World Health Organization. Hypertension. Geneva: WHO; 2023 [cited 9 June 2023]. Available at: https://www.who.int/news-room/fact-sheets/detail/hypertension. [Accessed 9 June 2023]
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39:3021–3104.
Mancia Chairperson G, Kreutz Co-Chair R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens 2023; 41:1874–2071.
Katsurada K, Shinohara K, Aoki J, Nanto S, Kario K. Renal denervation: basic and clinical evidence. Hypertens Res 2022; 45:198–209.
Sharp ASP, Tunev S, Schlaich M, Lee DP, Finn AV, Trudel J, et al. Histological evidence supporting the durability of successful radiofrequency renal denervation in a normotensive porcine model. J Hypertens 2022; 40:2068–2075.
Ogoyama Y, Tada K, Abe M, Nanto S, Shibata H, Mukoyama M, et al. Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials. Hypertens Res 2022; 45:210–220.
U.S. Food and Drug Administration. Premarket Approval (PMA): Symplicity Spyral™ Renal Denervation System. 2023. [cited 6 December 2023]. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220026. [Accessed 6 December 2023]
Ahmad Y, Francis DP, Bhatt DL, Howard JP. Renal denervation for hypertension: a systematic review and meta-analysis of randomized, blinded, placebo-controlled trials. JACC Cardiovasc Interv 2021; 14:2614–2624.
Ahmad Y, Kane C, Arnold AD, Cook CM, Keene D, Shun-Shin M, et al. Randomized blinded placebo-controlled trials of renal sympathetic denervation for hypertension: a meta-analysis. Cardiovasc Revasc Med 2022; 34:112–118.
Pisano A, Iannone LF, Leo A, Russo E, Coppolino G, Bolignano D. Renal denervation for resistant hypertension. Cochrane Database Syst Rev 2021; 11:CD011499.
Silverwatch J, Marti KE, Phan MT, Amin H, Roman YM, Pasupuleti V, et al. Renal denervation for uncontrolled and resistant hypertension: systematic review and network meta-analysis of randomized trials. J Clin Med 2021; 10:782.
Singh S, Rout A, Garg A. Renal denervation in hypertension: an updated meta-analysis of the randomized controlled trials. Catheter Cardiovasc Interv 2023; 102:663–671.
Fernandes A, David C, Pinto FJ, Costa J, Ferreira JJ, Caldeira D. The effect of catheter-based sham renal denervation in hypertension: systematic review and meta-analysis. BMC Cardiovasc Disord 2023; 23:249.
Agasthi P, Shipman J, Arsanjani R, Ashukem M, Girardo ME, Yerasi C, et al. Renal denervation for resistant hypertension in the contemporary era: a systematic review and meta-analysis. Sci Rep 2019; 9:6200.
Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, et al. RADIANCE II Investigators and Collaborators. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial. JAMA 2023; 329:651–661.
Kandzari DE, Townsend RR, Kario K, Mahfoud F, Weber MA, Schmieder RE, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol 2023; 82:1809–1823.
Kandzari DE, Mahfoud F, Weber MA, Townsend R, Parati G, Fisher NDL, et al. Clinical trial design principles and outcomes definitions for device-based therapies for hypertension: a consensus document from the Hypertension Academic Research Consortium. Circulation 2022; 145:847–863.
Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions (Version 6.3). Cochrane; 2022. Available at: https://training.cochrane.org/handbook/current. [Accessed 9 June 2023]
Khan K, Ter Riet G, Glanville J, Sowden A, Kleijnen J. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD Report 4 [2nd edition]. York: 2001.
Centre for Reviews and Dissemination (CRD). PROSPERO [online database]. York: Centre for Reviews and Dissemination,; 2011. Last updated 29 June 2015. [cited 1 July 2021]. Available at: http://www.crd.york.ac.uk/PROSPERO/. [Accessed 9 June 2023]
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372:n71.
Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021; 372:n160.
Higgins JPT, Savovic J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., et, al., editors. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane. 2022. Available at: https://training.cochrane.org/handbook/current/chapter-08. [Accessed 9 June 2023]
Pharmaceutical Benefits Advisory Committee (PBAC). Appendix 4 Heterogeneity of treatment effect across studies [web page]. Canberra: Australian Government Department of Health; 2016. [cited 13 July 2018]. Available at: https://pbac.pbs.gov.au/appendixes/appendix-4-heterogeneity-of-treatment-effect-across-studies.html. [Accessed 9 June 2023]
Team RCR. A language and environment for statistical computing Vienna. Austria R Foundation for Statistical Computing; 2022.
Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al. Welcome to the tidyverse. J Open Source Softw 2019; 4:1686.
Schwarzer G. meta: An R package for meta-analysis. R news 2007; 7:40–45.
Viechtbauer W. Conducting meta-analyses in {R} with the {metafor} package. J Stat Softw 2010; 36:1–48.
Mathias Harrer PC, Toshi Furukawa, David Daniel Ebert. dmetar: Companion R Package For the Guide ’Doing Meta-Analysis in R’. 2019.
Barbato E, Azizi M, Schmieder RE, Lauder L, Böhm M, Brouwers S, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroIntervention 2023; 18:1227–1243.
U.S. Food and Drug Administration. Premarket Application (PMA) for Pxxxxxx: ReCor Medical's Paradise Ultrasound Renal Denervation System - FDA Executive Summary. 2023.
Warchol-Celinska E, Prejbisz A, Kadziela J, Florczak E, Januszewicz M, Michalowska I, et al. Renal denervation in resistant hypertension and obstructive sleep apnea: randomized proof-of-concept phase II trial. Hypertension 2018; 72:381–390.
Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015; 385:1957–1965.
Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; (9756):1903–1909.
Bohm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 2020; 395:1444–1451.
Tsioufis C, Dimitriadis K, Kasiakogias A, Kalos T, Liatakis I, Koutra E, et al. Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome. J Hypertens 2017; 35:1100–1108.
Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. RADIANCE-HTN investigators. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 2021; 397:2476–2486.
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 391:2335–2345.
Rosa J, Widimsky P, Tousek P, Petrak O, Curila K, Waldauf P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension 2015; 65:407–413.
Schneider S, Promny D, Sinnecker D, Byrne RA, Muller A, Dommasch M, et al. Impact of sympathetic renal denervation: a randomized study in patients after renal transplantation (ISAR-denerve). Nephrol Dial Transplant 2015; 30:1928–1936.
Oliveras A, Armario P, Clara A, Sans-Atxer L, Vazquez S, Pascual J, De la Sierra A. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens 2016; 34:1863–1871.
Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, et al. SYMPLICITY HTN-Japan - first randomized controlled trial of catheter-based renal denervation in Asian patients. Circ J 2015; 79:1222–1229.
Fengler K, Rommel K-P, Blazek S, Besler C, Hartung P, von Roeder M, et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN). Circulation 2019; 139:590–600.
Mathiassen ON, Vase H, Bech JN, Christensen KL, Buus NH, Schroeder AP, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens 2016; 34:1639–1647.
Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend M, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 2015; 65:1202–1208.
Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393–1401.
Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res 2022; 45:221–231.
Jacobs L, Persu A, Huang Q-F, Lengele J-P, Thijs L, Hammer F, et al. European Network Coordinating Research on Renal Denervation. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Press 2017; 26:321–331.
Weber MA, Kirtane AJ, Weir MR, Radhakrishnan J, Das T, Berk M, et al. The REDUCE HTN: REINFORCE: randomized, sham-controlled trial of bipolar radiofrequency renal denervation for the treatment of hypertension. JACC Cardiovasc Interv 2020; 13:461–470.
Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014; 63:991–999.
de Jager RL, de Beus E, Beeftink MM, Sanders MF, Vonken EJ, Voskuil M, et al. SYMPATHY Investigators. Impact of medication adherence on the effect of renal denervation: the SYMPATHY trial. Hypertension 2017; 4:678–684.
Anna Moiseeva A, Caraus A, Ciobanu N, Moscalu V, Surev A, Abras M, et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. Eur J Prev Cardiolog 2019; 26: (Suppl 1): S164–S165.
Moiseeva A, Caraus A, Moscalu V, Ciobanu N, Abras M, Calenici O, et al. Sympathetic renal denervation treatment in resistant hypertension: one-year follow-up. Eur Heart J 2020; 41: (Suppl 2): 2785.
Gao JQ, Zhang H, Li LY, Wang X, Ye J, Liu ZJ. Comparison of a 5 F microtube-irrigated ablation catheter and a general ablation catheter in the treatment of resistant hypertension with renal denervation. Cardiovasc Innov Appl 2021; 6:81–89.
Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 2008; 172:137–159.
Barbato E, Azizi M, Schmieder RE, Lauder L, Bohm M, Brouwers S, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2023; 44:1313–1330.
Paz MA, de-La-Sierra A, Sáez M, Barceló MA, Rodríguez JJ, Castro S, et al. Treatment efficacy of antihypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine (Baltimore) 2016; 95:e4071.
U.S. Food and Drug Administration. General Issues Panel: Clinical Evaluation of Anti-Hypertensive Devices. Circulatory System Devices Panel Meeting: 2018.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903–1913.
Blood Pressure Lowering Treatment Trialists’ Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 2021; 398:1053–1064.
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386:2059–2068.
SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103–2116.
Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, et al. PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 2022; 400:1927–1937.
Staplin N, de la Sierra A, Ruilope LM, Emberson JR, Vinyoles E, Gorostidi M, et al. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. Lancet 2023; 401:2041–2050.
Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46:156–161.
Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, Wei FF, et al. International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA 2019; 322:409–420.
Townsend RR, Walton A, Hettrick DA, Hickey GL, Weil J, Sharp ASP, et al. Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention 2020; 16:89–96.
Kirtane AJ, Sharp ASP, Mahfoud F, Fisher NDL, Schmieder RE, Daemen J, et al. RADIANCE Investigators and Collaborators. Patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials. JAMA Cardiol 2023; 8:464–473.
Mahfoud F, Mancia G, Schmieder RE, Ruilope L, Narkiewicz K, Schlaich M, et al. Outcomes following radiofrequency renal denervation according to antihypertensive medications: subgroup analysis of the global SYMPLICITY registry DEFINE. Hypertension 2023; 80:1759–1770.
Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 2019; 40:3474–3482.
NCT01534299. Global SYMPLICITY Registry (GSR) DEFINE. 2012.
Mahfoud F, Azizi M, Daemen J, Sharp ASP, Patak A, Iglesias JF, et al. Real-world experience with ultrasound renal denervation utilizing home blood pressure monitoring: the Global Paradise System registry study design. Clin 2023; doi: 10.1007/s00392-023-02325-x.
doi: 10.1007/s00392-023-02325-x
NCT05027685. The “Global Paradise System” Registry. 2022.
Pisano A, Iannone LF, Leo A, Russo E, Coppolino G, Bolignano D. Renal denervation for resistant hypertension. Cochrane Database Syst Rev 2021; 2:CD011499.
Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, et al. SYMPLICITY HTN-3 Steering Committee Investigators. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet 2022; 400:1405–1416.
Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 2018; 72:e53–e90.
Champaneria MK, Patel RS, Oroszi TL. When blood pressure refuses to budge: exploring the complexity of resistant hypertension. Front 2023; 10:1211199.
Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Marešová V, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension 2017; 69:1113–1120.
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71:e127–e248.
Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the United States: comparison of the 2008 and 2018 American Heart Association scientific statements on resistant hypertension. Hypertension 2019; 73:424–431.
Sesa-Ashton G, Nolde JM, Muente I, Carnagarin R, Lee R, Macefield VG, et al. Catheter-based renal denervation: 9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension. Hypertension 2023; 80:811–819.
Al Ghorani H, Kulenthiran S, Recktenwald MJM, Lauder L, Kunz M, Götzinger F, et al. 10-year outcomes of catheter-based renal denervation in patients with resistant hypertension. J Am Coll Cardiol 2023; 81:517–519.
Vogt A, Dutzmann J, Nußbaum M, Hoyer D, Tongers J, Schlitt A, et al. Safety and efficacy of renal sympathetic denervation: a 9-year long-term follow-up of 24-h ambulatory blood pressure measurements. Front Cardiovasc Med 2023; 10:1210801.